The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Open accessAbstract
siRNAs that specifically silence the expression of cancer-related genes offer a therapeutic approach in oncology. However, it remains critical to determine the true mechanism of their therapeutic effects. Here, we describe the preclinical development of chemically modified siRNA targeting the essential cell-cycle proteins polo-like kinase 1 (PLK1) and kinesin spindle protein (KSP) in mice. siRNA formulated in stable nucleic acid lipid particles (SNALP) displayed potent antitumor efficacy in both hepatic and subcutaneous tumor models. This was correlated with target gene silencing following a single intravenous administration that was sufficient to cause extensive mitotic disruption and tumor cell apoptosis. Our siRNA formulations induced no measurable immune response, minimizing the potential for nonspecific effects. Additionally, RNAi-specific mRNA cleavage products were found in tumor cells, and their presence correlated with the duration of target mRNA silencing. Histological biomarkers confirmed that RNAi-mediated gene silencing effectively inhibited the target's biological activity. This report supports an RNAi-mediated mechanism of action for siRNA antitumor effects, suggesting a new methodology for targeting other key genes in cancer development with siRNA-based therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
RNA interference is mediated by 21- and 22-nucleotide RNAs
Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,310
Asymmetry in the Assembly of the RNAi Enzyme Complex
Schwarz, D. S., Hutvágner, G., Du, T., Xu, Z., Aronin, N., & Zamore, P. D. (2003) · Cell · doi:10.1016/s0092-8674(03)00759-1 · Cited by 2,922
CpG Motifs in Bacterial DNA and Their Immune Effects
Krieg, A. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064842 · Cited by 2,573
5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,183
Der, S. D., Zhou, A., Williams, B. R. G., & Silverman, R. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15623 · Cited by 1,816
Detection of circulating tumor necrosis factor after endotoxin administration
Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhaug, A., O'Dwyer, S., Dinarello, C. A., Cerami, A., Wolff, S. M., & Wilmore, D. W. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806093182301 · Cited by 1,677
RNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Self-citationTherapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
Passenger-Strand Cleavage Facilitates Assembly of siRNA into Ago2-Containing RNAi Enzyme Complexes
Matranga, C., Tomari, Y., Shin, C., Bartel, D. P., & Zamore, P. D. (2005) · Cell · doi:10.1016/j.cell.2005.08.044 · Cited by 1,211
Interfering with disease: a progress report on siRNA-based therapeutics
de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2310 · Cited by 1,203
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,168
Self-citationPolo-like kinases and the orchestration of cell division
Barr, F. A., Silljé, H. H. W., & Nigg, E. A. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1401 · Cited by 1,087
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Kleinman, M. E., Yamada, K., Takeda, A., Chandrasekaran, V., Nozaki, M., Baffi, J. Z., Albuquerque, R. J. C., Yamasaki, S., Itaya, M., Pan, Y., et al. (2008) · Nature · doi:10.1038/nature06765 · Cited by 929
Schiffelers, R. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh140 · Cited by 901
siRNA function in RNAi: A chemical modification analysis
CHIU, Y.-L., & RANA, T. M. (2003) · RNA · doi:10.1261/rna.5103703 · Cited by 860
Targeting polo-like kinase 1 for cancer therapy
Strebhardt, K., & Ullrich, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1841 · Cited by 841
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F., & Aigner, A. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302425 · Cited by 716
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1
Lénárt, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J. J., Hoffmann, M., Rettig, W. J., Kraut, N., & Peters, J.-M. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.046 · Cited by 653
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells
Czauderna, F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg393 · Cited by 623
Bartlett, D. W. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj439 · Cited by 592
Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo
Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571
Self-citationGilliet, M., Boonstra, A., Paturel, C., Antonenko, S., Xu, X.-L., Trinchieri, G., O'Garra, A., & Liu, Y.-J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020045 · Cited by 524
Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target
Peer, D., Park, E. J., Morishita, Y., Carman, C. V., & Shimaoka, M. (2008) · Science · doi:10.1126/science.1149859 · Cited by 493
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
Liu, X., & Erikson, R. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031523100 · Cited by 472
Cleavage of the siRNA passenger strand during RISC assembly in human cells
Leuschner, P. J. F., Ameres, S. L., Kueng, S., & Martinez, J. (2006) · EMBO reports · doi:10.1038/sj.embor.7400637 · Cited by 399
5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma
Poeck, H., Besch, R., Maihoefer, C., Renn, M., Tormo, D., Morskaya, S. S., Kirschnek, S., Gaffal, E., Landsberg, J., Hellmuth, J., et al. (2008) · Nature Medicine · doi:10.1038/nm.1887 · Cited by 387
Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382
Marques, J. T., Devosse, T., Wang, D., Zamanian-Daryoush, M., Serbinowski, P., Hartmann, R., Fujita, T., Behlke, M. A., & Williams, B. R. (2006) · Nature Biotechnology · doi:10.1038/nbt1205 · Cited by 380
A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium
Santel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V, Fisch, G., Dames, S., Löffler, K., Fechtner, M., Arnold, W., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302777 · Cited by 368
RNA interference and chemically modified small interfering RNAs
Manoharan, M. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.10.007 · Cited by 346
Malumbres, M., & Barbacid, M. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.008 · Cited by 338
von Marschall, Z., Scholz, A., Cramer, T., Schafer, G., Schirner, M., Oberg, K., Wiedenmann, B., Hocker, M., & Rosewicz, S. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.437 · Cited by 328
Spankuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M., & Strebhardt, K. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.24.1863 · Cited by 327
Passive tumor targeting of soluble macromolecules and drug conjugates.
Seymour, L. W. (1992) · PubMed · Cited by 316
Positional Effect of Chemical Modifications on Short Interference RNA Activity in Mammalian Cells
Prakash, T. P., Allerson, C. R., Dande, P., Vickers, T. A., Sioufi, N., Jarres, R., Baker, B. F., Swayze, E. E., Griffey, R. H., & Bhat, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050044o · Cited by 285
Overcoming the Innate Immune Response to Small Interfering RNA
Judge, A., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 284
Self-citationDiebold, S. S., Massacrier, C., Akira, S., Paturel, C., Morel, Y., & Reis e Sousa, C. (2006) · European Journal of Immunology · doi:10.1002/eji.200636617 · Cited by 283
Tao, W., South, V. J., Zhang, Y., Davide, J. P., Farrell, L., Kohl, N. E., Sepp-Lorenzino, L., & Lobell, R. B. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.003 · Cited by 273
Antitumor Activity of a Kinesin Inhibitor
Sakowicz, R., Finer, J. T., Beraud, C., Crompton, A., Lewis, E., Fritsch, A., Lee, Y., Mak, J., Moody, R., Turincio, R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3839 · Cited by 241
Chono, S., Li, S.-D., Conwell, C. C., & Huang, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.006 · Cited by 238
Misinterpreting the Therapeutic Effects of Small Interfering RNA Caused by Immune Stimulation
Robbins, M., Judge, A., Ambegia, E., Choi, C., Yaworski, E., Palmer, L., McClintock, K., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.131 · Cited by 220
Self-citationA Comprehensive View of Regulation of Gene Expression by Double-stranded RNA-mediated Cell Signaling
Geiss, G., Jin, G., Guo, J., Bumgarner, R., Katze, M. G., & Sen, G. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100137200 · Cited by 211
Ambegia, E., Ansell, S., Cullis, P., Heyes, J., Palmer, L., & MacLachlan, I. (2005) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2005.02.001 · Cited by 202
Self-citationSantel, A., Aleku, M., Keil, O., Endruschat, J., Esche, V, Durieux, B., Löffler, K., Fechtner, M., Röhl, T., Fisch, G., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302778 · Cited by 183
Heyes, J. A., Hall, K., Tailor, V., Lenz, R., & MacLachlan, I. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.02.012 · Cited by 126
Self-citationJohnson, E. F., Stewart, K. D., Woods, K. W., Giranda, V. L., & Luo, Y. (2007) · Biochemistry · doi:10.1021/bi7008745 · Cited by 118
Sarkar, S. N., Smith, H., Rowe, T. M., & Sen, G. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200655200 · Cited by 117
Targeting the Kinesin Eg5 to Monitor siRNA Transfection in Mammalian Cells
Barbieri-Weill, D., Garçon, L., Harper, M., Dumènil, D., Dautry, F., & Kress, M. (2002) · BioTechniques · doi:10.2144/02336st01 · Cited by 111
Rational combinations of siRNAs targeting Plk1 with breast cancer drugs
Spänkuch, B., Kurunci‐Csacsko, E., Kaufmann, M., & Strebhardt, K. (2007) · Oncogene · doi:10.1038/sj.onc.1210355 · Cited by 105
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance
McInnes, C., Mazumdar, A., Mezna, M., Meades, C. K., Midgley, C., Scaërou, F., Carpenter, L., Mackenzie, M., Taylor, P., Walkinshaw, M. D., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio825 · Cited by 99
Buhtoiarov, I. N., Lum, H. D., Berke, G., Sondel, P. M., & Rakhmilevich, A. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.309 · Cited by 88
A novel orthotopic tumor model to study growth factors and oncogenes in hepatocarcinogenesis.
Yao, X., Hu, J., Daniels, M., Yien, H., Lü, H., Sharan, H., Zhou, X., Zeng, Z., Li, T., Yang, Y., et al. (2003) · PubMed · Cited by 73
Lanuti, M., Rudginsky, S., Force, S. D., Lambright, E. S., Siders, W., Chang, M. Y., Amin, K. M., Kaiser, L. R., Scheule, R. K., & Albelda, S. Μ. (2000) · PubMed · Cited by 68
Misinterpreting the therapeutic effects of siRNA caused by immune stimulation
Robbins, M., Judge, A. D., Ambegia, E., Choi, C., Yaworski, E., Palmer, L., McClintock, K., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hgt.2008.131 · Cited by 41
Self-citationBeyond Double-Stranded RNA-Type I IFN Induction by 3pRNA and Other Viral Nucleic Acids
Schlee, M., Barchet, W., Hornung, V., & Hartmann, G. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-71329-6_11 · Cited by 34
Castro, J. E., Prada, C. E., Aguillon, R. A., Kitada, S., Fukuda, T., Motta, M., Wu, C. C. N., Dicker, F., Sun, G., Wang, J. Y. J., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404144 · Cited by 21
Cited by
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Self-citationTherapeutic siRNA silencing in inflammatory monocytes in mice
Leuschner, F., Dutta, P., Gorbatov, R., Novobrantseva, T. I., Donahoe, J. S., Courties, G., Lee, K. M., Kim, J. I., Markmann, J. F., Marinelli, B., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1989 · Cited by 839
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
Metadata
- Authors
- Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I.
- Venue
- Journal of Clinical Investigation
- Published
- 2009-03-02
- Volume
- 119
- Issue
- 3
- Pages
- 661-673
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2120421571
- Cited by
- 336
- References
- 62
- FWCI
- 12.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.